Hi All
Looks like momentum is moving towards talking about pre-referral treatment. MMV have an article in their March 2015 newsletter titled: Providing timely access to pre-referral treatment for severe malaria: how ready is the market in sub Saharan Africa.
Unfortunitely no mention of ArTiMist but the article does give all the reasons why ArTiMist should be accepted for pre-referral treatment.
Certainly a recommended read and easy to find.....google MMV and the newsletter pops up and just hit the article.
kippax
MMV Pre-referral treatment, severe malaria
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.015(11.1%) |
Mkt cap ! $157.7M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 15.0¢ | 14.0¢ | $106.6K | 736.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 487932 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 50000 | 1 |
View Market Depth
| Last trade - 15.36pm 16/08/2024 (20 minute delay) ? |
| ALA (ASX) Chart |